Case number 1:23-cv-00389
Actelion Pharmaceuticals US, Inc. et al v. Cipla Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 12, 2023 | 11 | ANSWER to 1 Complaint, , COUNTERCLAIM against Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc., Nippon Shinyaku Co., Ltd. by Cipla Limited, Cipla USA Inc..(Golden, Ronald) (Entered: 06/12/2023) (21) |
| Jun 12, 2023 | 12 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent InvaGen Pharmaceuticals, Inc., Corporate Parent Cipla (EU Limited) for Cipla USA Inc. filed by Cipla Limited, Cipla USA Inc.. (Golden, Ronald) (Entered: 06/12/2023) (2) |
| Jun 8, 2023 | 10 | NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA, Inc. Paragraph 3 Disclosures Regarding Discovery filed by Cipla Limited, Cipla USA Inc..(Golden, Ronald) (Entered: 06/08/2023) (2) |
| Apr 25, 2023 | N/A | SO ORDERED, re (9 in 1:23-cv-00389-GBW, 17 in 1:22-cv-01450-GBW) STIPULATED ORDER Regarding Consolidation of Actions filed by Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. Signed by Judge Gregory B. Williams on 4/25/23. Associated Cases: 1:22-cv-01450-GBW, 1:23-cv-00389-GBW (ntl) (Entered: 04/25/2023) (0) |
| Apr 25, 2023 | N/A | Case associated with lead case: Create association to 1:22-cv-01450-GBW. ALL PAPERS SHALL BE FILED IN LEAD CASE NO. 22-1450-GBW ONLY. (ntl) (Entered: 04/25/2023) (0) |
| Apr 21, 2023 | 9 | STIPULATION Regarding Consolidation of Actions, by Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc., Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd. (Balick, Steven) (Entered: 04/21/2023) (3) |
| Apr 18, 2023 | 7 | WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd.: For Cipla Limited waiver sent on 4/13/2023, answer due 6/12/2023. (Balick, Steven) (Entered: 04/18/2023) (1) |
| Apr 18, 2023 | 8 | WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd.: For Cipla USA Inc. waiver sent on 4/13/2023, answer due 6/12/2023. (Balick, Steven) (Entered: 04/18/2023) (1) |
| Apr 12, 2023 | N/A | Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. Associated Cases: 1:23-cv-00383-GBW, 1:23-cv-00389-GBW (rjb) (Entered: 04/12/2023) (0) |
| Apr 6, 2023 | 1 | COMPLAINT filed against Cipla Limited, Cipla USA Inc. (Filing fee $ 402, receipt number ADEDC-4106721.) - filed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jfm) (Entered: 04/06/2023) (Main Document) (12) |
| Apr 6, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 04/06/2023) (3) |
| Apr 6, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 13, 2023. Date of Expiration of Patent: June 25, 2030 (U.S. Patent No. 9,284,280); August 1, 2030 (U.S. Patent No. 8,791,122).Thirty Month Stay Deadline: 9/13/2025. (jfm) (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,122; 9,284,280. (jfm) (Entered: 04/06/2023) (1) |
| Apr 6, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. filed by Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. (jfm) (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nippon Shinyaku Co., Ltd. (jfm) (Entered: 04/06/2023) (1) |
| Apr 6, 2023 | N/A | No Summons Issued. (jfm) (Entered: 04/06/2023) (0) |
| Apr 6, 2023 | 1 | COMPLAINT filed against Cipla Limited, Cipla USA Inc. (Filing fee $ 402, receipt number ADEDC-4106721.) - filed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jfm) (Entered: 04/06/2023) (Exhibit A) (30) |
| Apr 6, 2023 | 1 | COMPLAINT filed against Cipla Limited, Cipla USA Inc. (Filing fee $ 402, receipt number ADEDC-4106721.) - filed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jfm) (Entered: 04/06/2023) (Civil Cover Sheet) (3) |
